Название файла: BSTQ_2011-07_Full-Issue.pdf
Размер файла: 370 Килобайт
Количество загрузок: 1543
The merger accelerates key strategic initiatives for both Talecris and Grifols as it creates a more efficient platform for manufacturing, innovation and global sales and marketing. The higher sale volumes of plasma derivatives such as albumin and IVIG, with double-digit increases, confirm the upward trend of the sector. Recurrent EBITDA of the business grew by 2.5% up to 212.1 million Euros. The BLOODCHIP® global distribution agreement strengthens Grifols´the Diagnostic Division, and is expected to generate revenues of between 50-100 million over the next 5 years.